![Roger Tell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Roger Tell
Technik-/Wissenschafts-/F&E-Leiter bei
ISOFOL MEDICAL AB
Profil
Roger Tell is currently the Director at Vivesto AB since 2022 and the Chief Scientific & Medical Officer at Isofol Medical AB since 2019.
Previously, he worked as the Vice President-Clinical Development at Aprea Therapeutics AB. Dr. Tell obtained his doctorate degree from Karolinska Institutet in 1998.
Aktive Positionen von Roger Tell
| Unternehmen | Position | Beginn |
|---|---|---|
| ISOFOL MEDICAL AB | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2019 |
| VIVESTO AB | Direktor/Vorstandsmitglied | 25.05.2022 |
Ehemalige bekannte Positionen von Roger Tell
| Unternehmen | Position | Ende |
|---|---|---|
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Corporate Officer/Principal | 01.02.2019 |
Ausbildung von Roger Tell
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
12
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivesto AB
 Vivesto AB Pharmaceuticals: GenericHealth Technology Develops cancer drugs based on nanotechnology for human and veterinary use | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Isofol Medical AB
 Isofol Medical AB Pharmaceuticals: MajorHealth Technology Provides novel folate-based pharmaceutical products | Health Technology |
